Andersson K, Fuxe K, Eneroth P, Härfstrand A, Agnati L F
Department of Histology and Neurobiology, Karolinska Institutet, Stockholm, Sweden.
Neuroendocrinology. 1988 Aug;48(2):188-200. doi: 10.1159/000125007.
Male rats were treated acutely with nicotine (4 x 2 mg/kg, 30-min time intervals, total treatment time 2 h) or exposed to cigarette smoke from 4 x 1 cigarette (30-min time intervals, total treatment time 2 h). Some rats were pretreated with the D1 dopamine (DA) receptor antagonist SCH 23390 (0.1-3.0 mg/kg, i.p.), or with the D2 DA receptor antagonists remoxipride and raclopride (1 mg/kg, i.p.), or with the 5-hydroxytryptamine 2 (5-HT2) receptor antagonist ketanserin (0.3 mg/kg, i.p.) 5 min before nicotine treatment or the acute intermittent exposure to cigarette smoke. Some rats were treated with the D1 DA receptor agonist SK&F 38393 (1-10 mg/kg, i.p.) 15 min, 30 min or 2 h before decapitation. Hypothalamic and pre-optic catecholamine (CA) levels were measured by quantitative histofluorimetry in discrete DA and noradrenaline (NA) nerve terminal systems. Serum thyroid-stimulating hormone (TSH), prolactin, luteinizing hormone (LH), follicle-stimulating hormone (FSH), vasopressin, corticosterone and testosterone levels were determined by radioimmunoassay procedures. Nicotine treatment and to a minor degree also acute intermittent exposure to cigarette smoke produced a reduction in serum prolactin, LH and TSH but not in serum FSH, vasopressin and testosterone levels. Nicotine treatment also increased serum corticosterone levels. Pretreatment with the D1 DA receptor antagonist SCH 23390 (1-3 mg/kg) counteracted the lowering of serum LH, but not of prolactin and TSH levels induced by nicotine or exposure to cigarette smoke. SCH 23390 alone (1-3 mg/kg) increased serum TSH levels. Remoxipride, raclopride or ketanserin did not counteract any of the neuro-endocrine actions induced by nicotine treatment. However, ketanserin alone lowered serum prolactin levels. SK&F 38393 increased serum TSH, prolactin and LH levels. It was found that nicotine treatment and exposure to cigarette smoke with few exceptions produced a depletion of CA stores in NA and DA nerve terminals of the hypothalamus, pre-optic area and median eminence which was counteracted by SCH 23390 (1 mg/kg) but not by remoxipride, raclopride (1 mg/kg) or ketanserin (0.3 mg/kg). The results indicate that D1 but not D2 DA or 5-HT2 receptors may modulate the NA and DA release in the median eminence, the hypothalamus and the pre-optic area induced by nicotinic cholinoceptor activation. Furthermore, D1 DA receptors in the median eminence may at least in part mediate the inhibitory effects of nicotine on LH but not on TSH and prolactin secretion, although there appears to exist a D1 DA receptor in the median eminence which inhibits TSH secretion.(ABSTRACT TRUNCATED AT 400 WORDS)
雄性大鼠被急性给予尼古丁(4×2毫克/千克,间隔30分钟,总治疗时间2小时),或暴露于4支香烟的烟雾中(间隔30分钟,总暴露时间2小时)。一些大鼠在尼古丁治疗或急性间歇性暴露于香烟烟雾前5分钟,预先给予D1多巴胺(DA)受体拮抗剂SCH 23390(0.1 - 3.0毫克/千克,腹腔注射),或D2 DA受体拮抗剂瑞莫必利和雷氯必利(1毫克/千克,腹腔注射),或5 - 羟色胺2(5 - HT2)受体拮抗剂酮色林(0.3毫克/千克,腹腔注射)。一些大鼠在断头前15分钟、30分钟或2小时给予D1 DA受体激动剂SK&F 38393(1 - 10毫克/千克,腹腔注射)。通过定量组织荧光法在离散的DA和去甲肾上腺素(NA)神经末梢系统中测量下丘脑和视前区的儿茶酚胺(CA)水平。通过放射免疫分析程序测定血清促甲状腺激素(TSH)、催乳素、黄体生成素(LH)、卵泡刺激素(FSH)、血管加压素、皮质酮和睾酮水平。尼古丁治疗以及在较小程度上急性间歇性暴露于香烟烟雾会导致血清催乳素、LH和TSH水平降低,但血清FSH、血管加压素和睾酮水平未降低。尼古丁治疗还会增加血清皮质酮水平。预先给予D1 DA受体拮抗剂SCH 23390(1 - 3毫克/千克)可抵消尼古丁或暴露于香烟烟雾引起的血清LH降低,但不能抵消催乳素和TSH水平的降低。单独使用SCH 23390(1 - 3毫克/千克)会增加血清TSH水平。瑞莫必利、雷氯必利或酮色林不能抵消尼古丁治疗引起的任何神经内分泌作用。然而,单独使用酮色林会降低血清催乳素水平。SK&F 38393会增加血清TSH、催乳素和LH水平。研究发现,除少数例外情况,尼古丁治疗和暴露于香烟烟雾会导致下丘脑、视前区和正中隆起的NA和DA神经末梢中的CA储存耗竭,SCH 23390(1毫克/千克)可抵消这种耗竭,但瑞莫必利、雷氯必利(1毫克/千克)或酮色林(0.3毫克/千克)不能。结果表明,D1而非D2 DA或5 - HT2受体可能调节由烟碱胆碱受体激活引起的正中隆起、下丘脑和视前区的NA和DA释放。此外,正中隆起中的D1 DA受体可能至少部分介导尼古丁对LH的抑制作用,但对TSH和催乳素分泌无抑制作用,尽管正中隆起中似乎存在一种抑制TSH分泌的D1 DA受体。(摘要截短至400字)